Hemocompatibility of drug-eluting coronary stents coated with sulfonated poly (styrene-block-isobutylene-block-styrene).
ABSTRACT The presence of polymer coating on a coronary stent is a major mediator of coronary inflammation reaction thereby affects re-endothelialization. Poly(styrene-block-isobutylene-block-styrene) (SIBS) is one of the most attractive alternatives to serve as stent coating, but has shown less than optimal biocompatibility. Increasing the sulfonic acid content in the polymer can result in increased strength and hydrophilicity. The present study was undertaken to determine the mechanism of action and in vivo efficacy of sulfonated SIBS (S-SIBS) designed specifically as a stent polymer with reduced inflammatory potential and greater endothelialization preservation potential. The blood compatibility of S-SIBS in vitro and its ability to support the attachment of human umbilical vein endothelial cells (HUVECs) were first assessed to get some insight into its potential use in vivo. Baer metal stent (BMS), S-SIBS-coated stent without drug (BMS Plus S-SIBS), standard drug-eluting stent (DES) and S-SIBS-coated drug-eluting stent (DES Plus S-SIBS) were then implanted in the coronary arteries of a porcine model. Neointimal hyperplasia was evaluated at 28 and 180 days, and re-endothelialization was evaluated at 7 and 28 days post stents implantation. The results showed that DES Plus S-SIBS exhibited similar ability to reduce neointimal hyperplasia but preserved endothelialization compared with standard DES. These results suggest potentially promising performance of S-SIBS-coated stent in human clinical applications of coronary stenting.
- SourceAvailable from: Jingan Li[Show abstract] [Hide abstract]
ABSTRACT: Driven by the complications occurring with bare metal stents (BMSs) and drug-eluting stents (DESs), concerns have been raised over strategies for long-term safety, with respect to preventing or inhibiting stent thrombosis (ST), restenosis and in-stent restenosis (ISR) in particularly. Surface modification is very important in constructing a buffer layer at the interface of the organic and inorganic materials, and in ultimately obtaining long-term biocompatibility. In this review, we summarize the developments in surface modification of implanted cardiovascular metal stents. This review focuses on the modification of metal stents via coating drugs or biomolecules to enhance anti-thrombosis, anti-restenosis and/or endothelialization. In addition, we indicate the probable future work involving the modification of the metallic blood-contacting surfaces of stents and other cardiovascular devices that are under development.Journal of Biomedical Materials Research Part A 03/2013; · 2.83 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: As a biostable elastomer, the hydrophobicity of styrenic block copolymer (SBC) intensely limits its biomedical applications. In order to overcome such shortcoming, the SBC films were grafted with hyaluronic acid (HA) using a coupling agent. The surface chemistry of the modified films was examined by ATR-FTIR and XPS techniques, and the surface morphology was visually described by AFM. The biological performances of the HA-modified films were evaluated by a series of experiments, such as protein adsorption, platelet adhesion, and in vitro cytocompatibility. It was found that the HA-modified samples showed a low adhesiveness to fibroblast at the initial stage; however, it stimulated the growth of fibroblast. The L929 fibroblast growth presented a strong dependence on the molecular weight (MW) of HA. The samples modified with 17kDa HA exhibited the worst wettability and platelet adhesion, while providing the best results of supporting fibroblast proliferation.Colloids and surfaces B: Biointerfaces 08/2013; 112C:146-154. · 4.28 Impact Factor
- [Show abstract] [Hide abstract]
ABSTRACT: Zwitterionic hyperbranched polyester (HBPE) synthesized on bare metal stents (BMS) surface by surface-initiated atom transfer radical polymerization (SI-ATRP) method. The modified BMS obtained was tested for its blood compatibility. The blood compatibility studies were including, platelet adhesion tests, hemolysis assay, morphological changes in RBCs, coagulation tests, PRT assay, complement activation, platelet activation, and the cytotoxicity was also investigated. The modified BMS surface does not cause platelets adherent, red blood cell disruption, hemolysis and does not induce complement and platelets activation. All results indicated that the modified BMS was blood compatible and no cytotoxicity. It has the potential use for biomedical applications.Journal of Colloid and Interface Science 01/2014; 420:88–96. · 3.55 Impact Factor